Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro ...
The Cologuard Plus home screening test [Image courtesy of Abbott/Exact Sciences]Abbott (NYSE: ABT) has received approval in ...
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...
ABBOTT PARK, Ill., March 31, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for over-the-counter, non ...
Abbott said its 15-minute, hand-held blood test could help rule out the need for imaging scans to check for tissue damage in the 24 hours following a possible concussion or traumatic brain injury.
Abbott's lab-based concussion test looks for two biomarkers in the blood, both of which have been closely linked to traumatic brain injuries when found in elevated concentrations. In studies, it was ...
Abbott, a global healthcare leader, announced today that the Cologuard Plus® test has received CE Mark under the European Union's In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results